Literature DB >> 912916

Production and characterization of an antiserum against pancreatic glucagon.

H Von Schenck.   

Abstract

To produce a carboxy-terminal specific antiserum against pancreatic glucagon, glucagon was coupled mainly via its amino-terminal histidine to thyroglobulin, using the amino group reactive pentandial at pH 7.0 for the conjugation procedure. After repeated immunization of rabbits, one high titer antiserum was obtained with a combining site recognizing a part of the carboxy-terminal portion of glucagon as judged from the cross-reaction curves with glucagon fragments, duck pancreatic glucagon and gut glucagon-like immunoreactive substances. There was no cross-reaction with secretin, vasoactive intestinal peptide, and gastric inhibitory peptide. In spite of strong immunoreactive similarities with the antiserum 30K (Unger) this antiserum results in determinations of a somewhat higher amount of plasma immunoreactive glucagon (IRG). The difference was found to depend on a higher content of IRG with a molecular size close to immunoglobulin IgG. A patient with agamma-globulinemia had no measurable IRG of molecular size close to that of IgG, indicating a possible competitive binding of some immunoglobulins to the antiserum.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 912916     DOI: 10.1016/0009-8981(77)90138-3

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

1.  Insulin resistance in type 1 (insulin-dependent) diabetes following hypoglycaemia--evidence for the importance of beta-adrenergic stimulation.

Authors:  S Attvall; J Fowelin; H von Schenck; I Lager; U Smith
Journal:  Diabetologia       Date:  1987-09       Impact factor: 10.122

2.  Glucagon immunoreactivity in plasma from normal and dystrophic mice.

Authors:  B Ahrén; I Lundquist
Journal:  Diabetologia       Date:  1982-04       Impact factor: 10.122

3.  Glucagon receptor of human liver. Studies of its molecular weight and binding properties, and its ability to activate hepatic adenylyl cyclase of non-obese and obese subjects.

Authors:  J N Livingston; K Einarsson; L Backman; S Ewerth; P Arner
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

4.  Glucagon, stress, and portal hypertension. Plasma glucagon levels and portal hypertension in relation to anesthesia and surgical stress.

Authors:  T J Johnson; E M Quigley; T E Adrian; G Jin; L F Rikkers
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

5.  Improved but not normalized glucose counter-regulation during glucagon infusion in Type 1 (insulin-dependent) diabetes.

Authors:  I Lager; H von Schenck; U Smith
Journal:  Diabetologia       Date:  1984-05       Impact factor: 10.122

6.  Early posthypoglycemic insulin resistance in man is mainly an effect of beta-adrenergic stimulation.

Authors:  S Attvall; B M Eriksson; J Fowelin; H von Schenck; I Lager; U Smith
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

7.  Plasma glucagon in diabetes of haemochromatosis: too low or too high?

Authors:  W A Muller; M Berger; H J Cüppers; P Berchtold; G Strohmeyer; A E Renold; J R Hofstetter; J J Gonvers
Journal:  Gut       Date:  1979-03       Impact factor: 23.059

8.  Functional studies in patients with the glucagonoma syndrome.

Authors:  J J Holst; S Helland; S Ingemannson; N B Pedersen; H von Schenck
Journal:  Diabetologia       Date:  1979-09       Impact factor: 10.122

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.